Life sciences companies and investors are currently managing a complex investment climate characterized by high interest rates, regulatory volatility, restricted venture capital markets, and a slow recovery in IPO activity. Despite these headwinds, the sector maintains momentum through strategic partnerships with major pharmaceutical and MedTech firms, allowing high-performing companies to secure essential capital and continue driving scientific innovation.
In this environment, alternative financing has transitioned from a niche option to a fundamental necessity. As operational costs rise and pricing/reimbursement landscapes shift, hybrid and crossover models—such as royalty financing, innovative debt structures, and flexible capital stacks—are fundamentally reshaping capital deployment and deal structures across the life sciences industry.
These hybrid structures serve as catalysts for growth and value creation, providing investors with early, less competitive access to MedTech and life sciences operators. Blended finance approaches allow companies to secure superior pricing and deal terms while de-risking investments and positioning investors for significant gains when market conditions improve. Furthermore, as M&A activity accelerates and acquirers seek to enter the development cycle earlier, hybrid financing acts as a vital bridge to acquisition, providing companies with necessary liquidity while offering investors structured protections and diverse exit paths.
Creative financing enables life sciences firms to keep pace with rapid scientific breakthroughs while maintaining the cash reserves required for development and commercial success. Simultaneously, investors are prioritizing deal structures that create shared value, whether through co-investing with venture capital firms or partnering with strategic players to mitigate risk.
To achieve success in this evolving market, investors and target companies should focus on these six actionable strategies:
1. Diversify financial risk to maintain competitiveness. In a saturated market, successful dealmakers must look beyond traditional binary “exit-or-bust” models. Utilizing royalties, build-to-buy, or partial-liquidity structures helps distribute financial exposure. These methods allow investors to capture upside during pivotal milestones, such as regulatory approvals, without forcing premature exits or excessive equity dilution for the company.
2. Prioritize rigorous metrics and measurement. Effective risk management requires robust internal metrics to evaluate hybrid deals. Key indicators include milestone-to-capital ratios, actual versus modeled probability-of-success curves, non-dilutive leverage, and portfolio-level exposure. Investors who master these measurement capabilities will define the next generation of market standards.
3. Align funding models with specific sector dynamics. Capital requirements vary significantly by sub-sector. In MedTech, hybrid financing can accelerate the path to commercialization by providing flexible capital during expensive clinical and scale-up phases, thereby reducing dilution. Conversely, for specialty pharma, royalty-based models may offer a more straightforward approach due to more predictable economics and fewer operational complexities. Utilizing specialized industry advisors can ensure these models align with stakeholder expectations.
4. Cultivate strategic syndicates early. Success often depends on building investor relationships and conducting due diligence well before a formal capital raise is required. A proactive, collaborative approach—offering strategic advice and expertise during the relationship-building phase—can lead to more favorable terms and a smoother fundraising process, reducing the pressure of competitive, late-stage rounds.
5. Integrate hybrids into core investment strategies. Rather than using hybrid structures opportunistically, embedding them into a core strategy can stabilize a portfolio. By combining high-growth, high-risk assets with de-risked, cash-flowing assets, investors can create a more resilient portfolio that performs consistently across various market cycles.
6. Leverage secondary markets for liquidity. Secondary markets provide new avenues for early investors to realize liquidity before traditional exits. This allows founders and investors to unlock capital even while clinical trials or regulatory milestones are pending, preventing forced sales under suboptimal market conditions. These markets also allow new investors to enter late-stage, de-risked companies with validated pipelines and established revenue streams.
The life sciences sector is at a critical inflection point. As high-ROI assets enter the market, hybrid financing offers the strategic, creative dealmaking framework necessary to drive both scientific progress and long-term commercial success.
Photo: sesame, Getty Images
Kristian (Krist) Werling is the global head of McDermott’s Health & Life Sciences practice, providing regulatory and transactional counsel to industry leaders and investors. He represents companies, healthcare providers, and PE/VC firms in complex transactional and regulatory matters.
Todd Finger represents clients in a full range of corporate transactions, including mergers, acquisitions, joint ventures, and restructurings. He advises clients in the biotechnology, medical device, healthcare, and consumer products sectors, among others.
